inclusion criteria: * hospitalized patient with clinical diagnosis of sars-cov-2 virus infection per world health organization criteria including positive nucleic acid test of any specimen (e.g., respiratory, blood, or other bodily fluid) within 2 weeks prior to screening. * symptoms suggestive of severe systemic illness with covid-19, which could include any of the following symptoms: fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal symptoms, or shortness of breath at rest, or respiratory distress. * clinical signs indicative of severe systemic illness with covid-19, which could include any of the following clinical signs: respiratory rate ≥ 30 per minutes, heart rate ≥ 125 per minute, spo2 ≤ 93% on room air, or pao2/fio2 ratio \< 300 mmhg. * men or women ≥18 but ≤80 years of age at the time of signing the informed consent. * patient is able to understand the purpose and risks of the study and provide signed and dated informed consent or have a legal representative provide consent and authorization to use protected health information (in accordance with national and local patient privacy regulations).

inclusion criteria: * hospitalized patient with clinical diagnosis of sars-cov-2 virus infection per world health organization criteria including positive nucleic acid test of any specimen (e.g., respiratory, blood, or other bodily fluid) within 2 weeks prior to screening. * symptoms suggestive of severe systemic illness with covid-19, which could include any of the following symptoms: fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal symptoms, or shortness of breath at rest, or respiratory distress. * clinical signs indicative of severe systemic illness with covid-19, which could include any of the following clinical signs: respiratory rate ≥ 30 per minutes, heart rate ≥ 125 per minute, spo2 ≤ 93% on room air, or pao2/fio2 ratio \< 300 mmhg. * men or women ≥18 but ≤80 years of age at the time of signing the informed consent. * patient is able to understand the purpose and risks of the study and provide signed and dated informed consent or have a legal representative provide consent and authorization to use protected health information (in accordance with national and local patient privacy regulations).

inclusion criteria: - hospitalized patient with clinical diagnosis of sars-cov-2 virus infection per world health organization criteria including positive nucleic acid test of any specimen (e.g., respiratory, blood, or other bodily fluid) within 2 weeks prior to screening. - symptoms suggestive of severe systemic illness with covid-19, which could include any of the following symptoms: fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal symptoms, or shortness of breath at rest, or respiratory distress. - clinical signs indicative of severe systemic illness with covid-19, which could include any of the following clinical signs: respiratory rate ≥ 30 per minutes, heart rate ≥ 125 per minute, spo2 ≤ 93% on room air, or pao2/fio2 ratio < 300 mmhg. - men or women ≥18 but ≤80 years of age at the time of signing the informed consent. - patient is able to understand the purpose and risks of the study and provide signed and dated informed consent or have a legal representative provide consent and authorization to use protected health information (in accordance with national and local patient privacy regulations).

inclusion criteria: - hospitalized patient with clinical diagnosis of sars-cov-2 virus infection per world health organization criteria including positive nucleic acid test of any specimen (e.g., respiratory, blood, or other bodily fluid) within 2 weeks prior to screening. - symptoms suggestive of severe systemic illness with covid-19, which could include any of the following symptoms: fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal symptoms, or shortness of breath at rest, or respiratory distress. - clinical signs indicative of severe systemic illness with covid-19, which could include any of the following clinical signs: respiratory rate ≥ 30 per minutes, heart rate ≥ 125 per minute, spo2 ≤ 93% on room air, or pao2/fio2 ratio < 300 mmhg. - men or women ≥18 but ≤80 years of age at the time of signing the informed consent. - patient is able to understand the purpose and risks of the study and provide signed and dated informed consent or have a legal representative provide consent and authorization to use protected health information (in accordance with national and local patient privacy regulations).